Researchers sought to determine whether a plerixafor-sparing regimen would prevent an increase in mobilization failures among patients with MM undergoing HCT.
In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves ...
3d
US Weekly on MSNBruce Springsteen Faces ‘Questions of Mortality’ Amid Wife Patti Scialfa’s Blood Cancer DiagnosisBruce Springsteen got candid about how wife Patti Scialfa’s multiple myeloma diagnosis has changed his perspective of life ...
Charley Steiner's multiple myeloma is in remission, marking a significant milestone in his private cancer journey. Jack Jones ...
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...
2d
GlobalData on MSNJ&J’s Darzalex combination gains expanded label for multiple myeloma in EuropeDarzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...
Publication shows that OGM can resolve translocation partners involving MYC in multiple myeloma (MM) more effectively than current methodsThe ...
This study explored the safety and efficacy of a CXCR2 agonist and plerixafor for mobilization of HSCs for hematopoietic stem cell transplantation in patients with MM.
Multiple myeloma is a type of cancer of the bone marrow. The cells in the bone marrow, called plasma cells, stop responding ...
In separate, live virtual events, Doris Hansen, MD, and Leyla O. Shune, MD, discuss options for a patient with ...
Revlimid (lenalidomide) is a brand-name oral capsule prescribed to treat multiple myeloma and certain other blood cell cancers in adults. This article covers topics such as side effects ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results